Peptimmune Initiates Phase I Study With A Novel Peptide Copolymer For The Treatment Of Multiple Sclerosis
Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.
